Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Senexin A 是一种有效且选择性的 CDK8 抑制剂,它还抑制 CDK19,Kd 值分别为0.83μM 和0.31μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 438 | 现货 | ||
2 mg | ¥ 639 | 现货 | ||
5 mg | ¥ 970 | 现货 | ||
10 mg | ¥ 1,490 | 现货 | ||
25 mg | ¥ 2,860 | 现货 | ||
50 mg | ¥ 4,230 | 现货 | ||
100 mg | ¥ 5,920 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 983 | 现货 |
产品描述 | Senexin A is an effective and selective CDK8 inhibitor that also inhibits CDK19 with Kd values of 0.83 microns and 0.31 microns, respectively. |
靶点活性 | CDK19:0.31 μm, CDK8:0.83 μM |
体外活性 | Senexin A inhibited CDK8 and CDK19 ATP site binding with Kd50 of 0.83 μM and 0.31 μM, respectively and CDK8 kinase activity with IC50 of 0.28 μM.CDK8 stimulates Wnt/β-catenin, and Senexin A inhibits β-catenin–dependent transcription in HCT116 colon carcinoma cells. |
体内活性 | Five daily treatment of Senexin A fully reverses tumor-promoting effect of chemotherapy. Senexin A shows no detectable toxicity as well as no significant effects on body weight, organ weights, or blood cell counts in C57BL/6 mice during the treatment. This effect of doxorubicin treatment is completely abolished, however, when doxorubicin injection is followed by administration of Senexin A. Senexin A treatment strongly improves the response of A549/MEF tumors to doxorubicin. |
动物实验 | Tumor-free C57BL/6-derived SCID mice were injected with a single dose of doxorubicin or carrier control.?Five days later, mice received. injection of 2 × 10^6 human A549 lung carcinoma cells, and tumor take was measured over 4 wk. |
分子量 | 274.32 |
分子式 | C17H14N4 |
CAS No. | 1366002-50-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (364.54 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.6454 mL | 18.2269 mL | 36.4538 mL | 91.1344 mL |
5 mM | 0.7291 mL | 3.6454 mL | 7.2908 mL | 18.2269 mL | |
10 mM | 0.3645 mL | 1.8227 mL | 3.6454 mL | 9.1134 mL | |
20 mM | 0.1823 mL | 0.9113 mL | 1.8227 mL | 4.5567 mL | |
50 mM | 0.0729 mL | 0.3645 mL | 0.7291 mL | 1.8227 mL | |
100 mM | 0.0365 mL | 0.1823 mL | 0.3645 mL | 0.9113 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Senexin A 1366002-50-7 Cell Cycle/Checkpoint CDK Cyclin dependent kinase Inhibitor inhibit inhibitor